Published in J Virol on June 06, 2012
Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A (2013) 2.05
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog (2013) 1.65
Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. PLoS One (2015) 1.39
CD4-induced activation in a soluble HIV-1 Env trimer. Structure (2014) 1.38
A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J Virol (2013) 1.25
HIV-1 envelope glycoprotein structure. Curr Opin Struct Biol (2013) 1.19
Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nat Commun (2015) 1.14
Analysis of overlapped and noisy hydrogen/deuterium exchange mass spectra. J Am Soc Mass Spectrom (2013) 1.06
Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. Structure (2013) 1.00
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. J Virol (2015) 1.00
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins (2014) 0.99
To dream the impossible dream: universal influenza vaccination. Curr Opin Virol (2013) 0.98
All-atom ensemble modeling to analyze small-angle x-ray scattering of glycosylated proteins. Structure (2013) 0.96
Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J Virol (2014) 0.91
Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J Virol (2013) 0.91
A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption. Biochemistry (2013) 0.90
Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. J Virol (2012) 0.88
A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS Comput Biol (2013) 0.88
Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J Virol (2014) 0.88
Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS (2013) 0.85
Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate. PLoS One (2015) 0.83
Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res (2014) 0.83
The influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop. PLoS One (2013) 0.82
Protein stability: a crystallographer's perspective. Acta Crystallogr F Struct Biol Commun (2016) 0.81
Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality. Retrovirology (2013) 0.80
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog (2017) 0.79
Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Protein Expr Purif (2013) 0.79
In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells. Front Microbiol (2016) 0.79
Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region. Structure (2016) 0.79
Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. Retrovirology (2013) 0.77
HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. Retrovirology (2016) 0.77
Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. Structure (2016) 0.76
Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. Biochemistry (2016) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion. Viruses (2016) 0.75
Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. J Virol (2016) 0.75
HIV and SIV Maintain High Levels of Infectivity in the Complete Absence of Mucin Type O-Glycosylation. J Virol (2017) 0.75
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. Biophys J (1999) 13.18
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Primary structure effects on peptide group hydrogen exchange. Proteins (1993) 10.79
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Determination of domain structure of proteins from X-ray solution scattering. Biophys J (2001) 10.39
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
X-ray solution scattering (SAXS) combined with crystallography and computation: defining accurate macromolecular structures, conformations and assemblies in solution. Q Rev Biophys (2007) 9.07
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics (2006) 8.72
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 8.30
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A (2000) 4.44
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
FoXS: a web server for rapid computation and fitting of SAXS profiles. Nucleic Acids Res (2010) 3.91
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol (1998) 3.60
Structure and flexibility within proteins as identified through small angle X-ray scattering. Gen Physiol Biophys (2009) 3.24
Additive empirical force field for hexopyranose monosaccharides. J Comput Chem (2008) 3.23
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature (2007) 3.01
Semi-automated data processing of hydrogen exchange mass spectra using HX-Express. J Am Soc Mass Spectrom (2006) 2.92
Using situs for flexible and rigid-body fitting of multiresolution single-molecule data. J Struct Biol (2001) 2.88
Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog (2006) 2.81
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
CHARMM Additive All-Atom Force Field for Glycosidic Linkages between Hexopyranoses. J Chem Theory Comput (2009) 2.61
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog (2010) 2.55
Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry. J Mass Spectrom (1997) 2.54
Analysis of X-ray and neutron scattering from biomacromolecular solutions. Curr Opin Struct Biol (2007) 2.50
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol (1998) 2.28
Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology (2003) 2.25
Identification and characterization of EX1 kinetics in H/D exchange mass spectrometry by peak width analysis. J Am Soc Mass Spectrom (2006) 2.25
Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell (2010) 2.22
Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol (2007) 2.19
Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog (2009) 2.07
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol (2010) 1.77
Amide hydrogen exchange determined by mass spectrometry: application to rabbit muscle aldolase. Biochemistry (1996) 1.71
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol (2012) 1.58
Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc Natl Acad Sci U S A (2010) 1.54
Prospects of HIV Env modification as an approach to HIV vaccine design. Curr HIV Res (2007) 1.48
Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem (2010) 1.48
The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J Virol (2000) 1.47
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med (2011) 1.46
Toward an antibody-based HIV-1 vaccine. Annu Rev Med (2010) 1.45
Distinct structures of scrapie prion protein (PrPSc)-seeded versus spontaneous recombinant prion protein fibrils revealed by hydrogen/deuterium exchange. J Biol Chem (2009) 1.27
Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods (2010) 1.17
Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A (2011) 1.16
Investigating solution-phase protein structure and dynamics by hydrogen exchange mass spectrometry. Curr Protoc Protein Sci (2009) 1.13
Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. J Virol (2010) 1.11
Functional visualization of viral molecular motor by hydrogen-deuterium exchange reveals transient states. Nat Struct Mol Biol (2005) 1.10
An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch Virol (1992) 1.06
Characterization of protein N-glycosylation. Methods Enzymol (2005) 1.05
Ultracentrifugal analysis of molecular mass of glycoproteins of unknown or ill-defined carbohydrate composition. Methods Enzymol (2000) 1.05
Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One (2008) 0.99
Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS Res Hum Retroviruses (1993) 0.95
The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution. FEBS Lett (1995) 0.90
Binding of full-length HIV-1 gp120 to CD4 induces structural reorientation around the gp120 core. Biophys J (2006) 0.76
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci U S A (2008) 2.09
Why primate models matter. Am J Primatol (2014) 2.05
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol (2007) 2.05
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Experimental pK(a) values of buried residues: analysis with continuum methods and role of water penetration. Biophys J (2002) 1.93
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol (2015) 1.64
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr (2003) 1.55
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol (2004) 1.49
Novel TRIM5 isoforms expressed by Macaca nemestrina. J Virol (2007) 1.40
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 1.30
Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr (2006) 1.29
The Prohead-I structure of bacteriophage HK97: implications for scaffold-mediated control of particle assembly and maturation. J Mol Biol (2011) 1.27
A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J Virol (2013) 1.25
Time-resolved molecular dynamics of bacteriophage HK97 capsid maturation interpreted by electron cryo-microscopy and X-ray crystallography. J Struct Biol (2005) 1.24
Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol (2010) 1.21
Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 1.17
Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J Virol (2006) 1.15
Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood (2013) 1.13
Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS (2007) 1.08
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol (2015) 1.07
Dynamics and stability in maturation of a T=4 virus. J Mol Biol (2009) 1.07
Analysis of overlapped and noisy hydrogen/deuterium exchange mass spectra. J Am Soc Mass Spectrom (2013) 1.06
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01
Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J Med Primatol (2008) 1.00
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. J Virol (2015) 1.00
Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One (2008) 0.99
Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One (2011) 0.98
All-atom ensemble modeling to analyze small-angle x-ray scattering of glycosylated proteins. Structure (2013) 0.96
Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. AIDS Res Hum Retroviruses (2004) 0.96
Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses. J Virol (2008) 0.96
Variable prevalence and functional diversity of the antiretroviral restriction factor TRIMCyp in Macaca fascicularis. J Virol (2011) 0.95
DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Vaccine (2005) 0.94
Kinetic and structural investigations of the allosteric site in human epithelial 15-lipoxygenase-2. Biochemistry (2009) 0.93
Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state. J Virol (2012) 0.93
Evolution of the antiretroviral restriction factor TRIMCyp in Old World primates. PLoS One (2010) 0.92
Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge. J Med Primatol (2007) 0.91
Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J Virol (2013) 0.91
Both CD1d antigen presentation and interleukin-12 are required to activate natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 0.90
Hexamers of the type II secretion ATPase GspE from Vibrio cholerae with increased ATPase activity. Structure (2013) 0.89
Maturation of a tetravirus capsid alters the dynamic properties and creates a metastable complex. Virology (2005) 0.89
Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology (2009) 0.88
Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina. J Med Primatol (2004) 0.87
Persistence of low levels of simian immunodeficiency virus in macaques that were transiently viremic by conventional testing. Virology (2004) 0.86
Multigene DNA prime-boost vaccines for SHIV89.6P. J Med Primatol (2003) 0.86
Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine (2008) 0.84
Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol (2007) 0.81
Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection. J Med Primatol (2013) 0.81
Isolation of monoclonal antibodies with predetermined conformational epitope specificity. PLoS One (2012) 0.81
R5-SHIV induces multiple defects in T cell function during early infection of rhesus macaques including accumulation of T reg cells in lymph nodes. PLoS One (2011) 0.80
Simian immunodeficiency virus-induced alterations in monocyte production of tumor necrosis factor alpha contribute to reduced immune activation in sooty mangabeys. J Virol (2012) 0.80
Dynamics of envelope evolution in clade C SHIV-infected pig-tailed macaques during disease progression analyzed by ultra-deep pyrosequencing. PLoS One (2012) 0.79
Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Protein Expr Purif (2013) 0.79
HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS. AIDS (2004) 0.79
Dysregulation of multiple inflammatory molecules in lymph node and ileum of macaques during RT-SHIV infection with or without antiretroviral therapy. J Med Primatol (2014) 0.78
Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation. AIDS (2015) 0.77
Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates. J Virol (2016) 0.76
Peripheral blood invariant natural killer T cells of pig-tailed macaques. PLoS One (2012) 0.76
Expression of the memory marker CD45RO on helper T cells in macaques. PLoS One (2013) 0.76
Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1. Bioorg Med Chem (2009) 0.75
How dental team members describe adverse events. J Am Dent Assoc (2016) 0.75
Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression. PLoS One (2013) 0.75
Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection. Clin Vaccine Immunol (2007) 0.75
Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. J Virol (2016) 0.75
Extracellular Matrix Proteins Mediate HIV-1 gp120 Interactions with α4β7. J Virol (2017) 0.75
Classifying Adverse Events in the Dental Office. J Patient Saf (2017) 0.75
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. bioRxiv (2020) 0.75